Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 10/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.76 |
| ▸ | CDC7 | O00311 | 1/20 | 0.76 |
| ▸ | PLK4 | O00444 | 1/20 | 0.76 |
| ▸ | AURKA | O14965 | 1/20 | 0.76 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.76 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.76 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.76 |
| ▸ | PRKCG | P05129 | 1/20 | 0.76 |
| ▸ | LCK | P06239 | 1/20 | 0.76 |
| ▸ | PIM1 | P11309 | 1/20 | 0.76 |
| ▸ | PRKACA | P17612 | 1/20 | 0.76 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.76 |
| ▸ | CDK2 | P24941 | 1/20 | 0.76 |
| ▸ | MARK3 | P27448 | 1/20 | 0.76 |
| ▸ | AKT1 | P31749 | 1/20 | 0.76 |
| ▸ | AKT2 | P31751 | 1/20 | 0.76 |
| ▸ | FLT4 | P35916 | 1/20 | 0.76 |
| ▸ | FLT3 | P36888 | 1/20 | 0.76 |
| ▸ | PRKCI | P41743 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4003709 | 0.94 | ROCK1 (0.89) | ROCK1RPS6KA5CDC7PLK4AURKA | |
| SCHEMBL4000013 | 0.94 | ROCK1 (0.89) | ROCK1RPS6KA5CDC7PLK4AURKA | |
| SCHEMBL4008426 | 0.94 | ROCK1 (0.89) | ROCK1RPS6KA5CDC7PLK4AURKA | |
| SCHEMBL4002958 | 0.93 | ROCK1 (0.87) | ROCK1RPS6KA5CDC7PLK4AURKA | |
| SCHEMBL4004963 | 0.93 | ROCK1 (0.87) | ROCK1RPS6KA5CDC7PLK4AURKA | |
| SCHEMBL3994133 | 0.93 | ROCK1 (0.87) | ROCK1RPS6KA5CDC7PLK4AURKA | |
| SCHEMBL4000963 | 0.93 | ROCK1 (0.89) | ROCK1RPS6KA5CDC7PLK4AURKA | |
| SCHEMBL4008349 | 0.93 | ROCK1 (0.86) | ROCK1RPS6KA5CDC7PLK4AURKA | |
| SCHEMBL4004403 | 0.92 | ROCK1 (0.85) | ROCK1RPS6KA5CDC7PLK4AURKA | |
| Gsk-248233A SCHEMBL4004560 | 0.92 | ROCK1 (1.00) | ROCK1RPS6KA5CDC7PLK4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547779-B2 | Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-06-16 | — | — | US | claimed |
| EP-1675552-A4 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-06-03 | — | — | EP | claimed |
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-25 | — | — | US | claimed |
| EP-1675552-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | claimed |
| WO-2005037197-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | claimed |
| US-7547779-B2 | Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| EP-1675552-A4 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-06-03 | — | — | EP | disclosed |
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-25 | — | — | US | disclosed |
| EP-1675552-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005037197-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | TNK2, ROCK1, ARHGDIB | ROCK1 2/4885RPS6KA5 99/4885CDC7 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.